Berkshire Biomedical, a Dallas, TX-based digital health company developing a virtual care and prescription drug management system, completed a $3m funding.
The backers were not disclosed.
The company intends to use the funds to continue to expand its development efforts.
Led by Thomas M. Rouse, Founder and Chairman, Berkshire Biomedical provides the Computerized Oral Prescription Administration (COPA®) system, which is currently under review with the U.S. Food and Drug Administration for market clearance.
The COPA™ System was designed as a virtual care and prescription drug delivery system that is pioneering the use of biometric authentication at the point-of-care in a hand-held, mobile-enabled device that receives actionable dosing parameters and transmits real-time event data to a HIPAA compliant cloud platform for storage and potential analytics.
The system provides a means for the patient’s prescribed medications to be stored in a delivery unit; for a medical provider to remotely schedule the patient’s prescribed medications; to provide notification to the patient when the prescribed medications are due to be taken; to release the prescribed medications into the mouthpiece, on the patient’s command; and to provide to the medical provider a history of the event.